2024
DOI: 10.1016/j.ekir.2024.01.020
|View full text |Cite
|
Sign up to set email alerts
|

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

F.J. Roca Oporto,
C. Andrades Gómez,
G. Montilla Cosano
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 26 publications
0
1
0
Order By: Relevance
“…For patients with ADPKD, this measure can vary significantly due to factors affecting kidney function [53] and treatment effects [54,55]. Clinical trials have noted marked increases in the 24 h urine volume to a median of 6 L/day during tolvaptan treatment [54][55][56]. Furthermore, increased hydration-recommended at approximately 2 to 3 L daily-can suppress vasopressin levels and potentially slow ADPKD progression [57].…”
Section: Urine Output and Ureteral Jet Effectmentioning
confidence: 99%
“…For patients with ADPKD, this measure can vary significantly due to factors affecting kidney function [53] and treatment effects [54,55]. Clinical trials have noted marked increases in the 24 h urine volume to a median of 6 L/day during tolvaptan treatment [54][55][56]. Furthermore, increased hydration-recommended at approximately 2 to 3 L daily-can suppress vasopressin levels and potentially slow ADPKD progression [57].…”
Section: Urine Output and Ureteral Jet Effectmentioning
confidence: 99%